The statistical analysis of treatment effects in 24‐hour ambulatory blood pressure recordings
MR Marler, RG Jacob, JP Lehoczky… - Statistics in …, 1988 - Wiley Online Library
This paper presents a statistical analysis of treatment effects in 24‐hour ambulatory blood
pressure recordings. The statistical models account for circadian rhythms, subject effects …
pressure recordings. The statistical models account for circadian rhythms, subject effects …
Effects of carvedilol on renal function
AG Dupont - European journal of clinical pharmacology, 1990 - Springer
A randomized, double-blind, placebo-controlled study was conducted to study the effects of
acute and chronic administration of carvedilol in essential hypertension, with special …
acute and chronic administration of carvedilol in essential hypertension, with special …
Formulation for the prevention of cardiovascular disease
NJ Wald, MR Law - US Patent 8,470,868, 2013 - Google Patents
This invention relates to a method for the prevention of cardiovascular disease, a formulation
for the prevention of cardiovascular disease, the use of specified active principals for the …
for the prevention of cardiovascular disease, the use of specified active principals for the …
[HTML][HTML] β2-Adrenergic Receptor-Dependent Attenuation of Hypoxic Pulmonary Vasoconstriction Prevents Progression of Pulmonary Arterial Hypertension in …
H Nagai, I Kuwahira, DO Schwenke, H Tsuchimochi… - PloS one, 2014 - journals.plos.org
In sleep apnea syndrome (SAS), intermittent hypoxia (IH) induces repeated episodes of
hypoxic pulmonary vasoconstriction (HPV) during sleep, which presumably contribute to …
hypoxic pulmonary vasoconstriction (HPV) during sleep, which presumably contribute to …
Bioequivalence of two tablet formulations of nadolol using single and multiple dose data: assessment using stereospecific and nonstereospecific assays
NR Srinivas, WH Barr, WC Shyu, E Mohandoss… - Journal of …, 1996 - Elsevier
Nadolol, a nonspecific β-blocker, is a racemate composed of equal amounts of four
stereoisomers, namely, SQ-12148, SQ-12149, SQ-12150, and SQ-12151. In an open-label …
stereoisomers, namely, SQ-12148, SQ-12149, SQ-12150, and SQ-12151. In an open-label …
Dose proportionality of nadolol pharmacokinetics after intravenous administration to healthy subjects
RA Morrison, SM Singhvi, WA Creasey… - European journal of …, 1988 - Springer
To support the increasing use of intravenous β-blockers during cardiovascular emergency
and surgery, dose proportionality of pharmacokinetics of nadolol was evaluated after …
and surgery, dose proportionality of pharmacokinetics of nadolol was evaluated after …
A randomized prospective comparison of nadolol, captopril with or without ticlopidine on disease progression in IgA nephropathy
IKP CHENG, GX Fang, MC Wong, YL Ji, KW Chan… - …, 1998 - Wiley Online Library
To determine if angiotensin converting enzyme inhibitors (ACEI) and antiplatelet agents
have any added advantages over beta‐blockers in preventing disease progression in IgA …
have any added advantages over beta‐blockers in preventing disease progression in IgA …
[图书][B] Фармакоэпидемиологическая и фармакоэкономическая оценка лечения артериальной гипертензии
ВП Вдовиченко - 2012 - elibrary.ru
В данной монографии изложены методы и результаты фармакоэпидемиологических и
фармакоэкономических исследований пациентов с артериальной гипертензией …
фармакоэкономических исследований пациентов с артериальной гипертензией …
Systemic and renal hemodynamic effects of celiprolol in essential hypertensives
AR Lucarini, A Salvetti - The American Journal of Cardiology, 1988 - Elsevier
To evaluate the humoral and hemodynamic (both systemic and renal) effects of celiprolol
and to assess whether these effects are at least partially due to the activation of dopamine …
and to assess whether these effects are at least partially due to the activation of dopamine …
Formulation for the prevention of cardiovascular disease
NJ Wald, MR Law - US Patent 10,357,503, 2019 - Google Patents
This invention relates to a method for the prevention of cardiovascular disease, a formulation
for the prevention of cardiovascular disease, the use of specified active principals for the …
for the prevention of cardiovascular disease, the use of specified active principals for the …